Water-soluble carbosilane dendrimers protect phosphorothioate oligonucleotides from binding to serum proteins by Chenco, Louis et al.
PAPER www.rsc.org/obc | Organic & Biomolecular Chemistry
Water-soluble carbosilane dendrimers protect phosphorothioate
oligonucleotides from binding to serum proteins
Louis Chonco,a Jesus F. Bermejo-Martı´n,a Paula Ortega,b Dzmitry Shcharbin,d Elzbieta Pedziwiatr,d
Barbara Klajnert,d F. Javier de la Mata,*b Ramon Eritja,c Rafael Go´mez,*b Maria Bryszewska*d and
Ma Angeles Mun˜oz-Fernandez*a
Received 16th March 2007, Accepted 27th April 2007
First published as an Advance Article on the web 14th May 2007
DOI: 10.1039/b703989a
Treatment of dendriplexes formed between water-soluble carbosilane dendrimers and phosphorothioate
oligodeoxynucleotides (ODN) with the anionic detergent sodium dodecyl sulfate disrupted the
complexes indicating that the nature of the union in such dendriplexes is merely electrostatic. However,
dendriplexes were not dissociated by serum proteins like bovine or human serum albumins, as assessed
by gel electrophoresis and ﬂuorescence experiments. This would imply a dendrimer-mediated protective
effect able to prevent ODN interactions with serum proteins and additionally could translate into a
reduction of the ODN doses needed to achieve the biological effects. The employment of carbosilane
dendrimers as carriers may solve the problem of ODN kidnapping by plasmatic proteins as a key
drawback for therapeutics involving ODNs. As examples, transfection processes on normal primary
peripheral blood cells and diagnosis of HIV infection in the presence of serum have been assayed.
Introduction
In the last few years, many anti-viral drugs have been developed
to ﬁght HIV infection, and proven to control infection. However,
many phase II and III trials have reported severe side effects (i.e.,
liver toxicity), but particularly the emergence of drug-resistant
strains. Moreover, all the current therapies do not reach all target
cells (i.e., inside tissues and the central nervous system) and are
not able to eradicate latently infected cells.1 The existence of viral
reservoirsmakes viral eradication nearly impossible with the drugs
available to date. All of this makes necessary the development of
new alternative therapeutic approaches to achieve better efﬁciency
with less adverse effects. Gene therapy (GT) represents one of
those new therapeutic approaches. However, GT is undergoing
some troubles due to the problems that viral vectors present
as vehicles for delivery of nucleic acids.2 For instance, the use
of viral vectors suffers from adverse effects, such as immune
reaction against the viral vector or lymphoproliferative syndromes
associated with oncogene deregulation. Besides, the consequences
of the incorporation of non-human genetic material into human
cells are still difﬁcult to predict. An additional problem is the
oligonucleotides’ tendency to bind non-speciﬁcally to serum pro-
teins that decreases their bioavailability, making necessary higher
doses for accomplishing a desired therapeutic effect. In some cases,
such non-speciﬁc binding to proteins can induce toxic effects,
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especially for the phosphorothioate oligodeoxynucleotide (ODN)
derivatives.3 Bovine serum albumin (BSA) and human serum
albumin (HSA) bind ODNs, inducing their uptake by cells of the
reticulo-endothelial system and not allowing them to reach the
extravascular space. Serum protein binding to ODN avoids thus
the overall interaction of oligonucleotides with cells.3a,4 Several
other proteins also bind ODNs, and the physiological state of the
cell inﬂuences the binding patterns.5 Some strategies have been
proposed to avoid ODN binding to serum proteins, for instance,
the use of vehicles such as cationic lipid carriers (lipoplexes)6 or
dendrimers (dendriplexes).7 One of the crucial impediments for
successful systemicODNorDNAtransferwith lipoplex exhibiting
a positive global charge, seems to be their inactivation because of
the non-speciﬁc binding of such liposomes with anionic serum
proteins8 as well as side-effects like lung inﬂammatory reactions.9
Dendrimers emerge as an alternative approach to liposomes and
polymeric systems for drug delivery. Their major advantages
are the uniform structure, multiple sites of attachment and the
versatility to modify their skeletons and surfaces, allowing a
precise characterization of the interaction of dendrimer–drug.
Potential transfecting agents based on PAMAM,10 phosphorus-
containing11 dendrimers or some small amphiphilic dendrimers12
have shown transfecting activity even in the presence of serum.
Although several studies have been published concerning the
interaction between PAMAM dendrimers and BSA,13 however, as
far as we know, there is only one study reporting on the interaction
between PAMAM-containing dendriplexes and serum proteins.14
Water-soluble carbosilane dendrimers containing ammonium
or amine groups at their periphery have been recently described
by our groups as biocompatible molecules with good perspectives
as non-viral carriers for ODN.15 In this work, we describe
the interactions between albumin and the dendriplexes formed
between ODN and second generation carbosilane dendrimers
having ammonium groups at their periphery (see Fig. 1) by gel
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Fig. 1 Molecular representation of the ammonium-terminated carbosilane dendrimers 1–4.
electrophoresis and ﬂuorescence spectroscopy. Here we prove a
dendrimer-mediated protection of ODNs from binding to serum
proteins to evaluate their use in some biomedical applications for
HIV infection research.
Results and discussion
We have published that second generation ammonium-terminated
carbosilane dendrimers have shown good toxicity proﬁles in
PBMCs primary cell culture models and erythrocytes over ex-
tended periods, employing different approaches such as evalu-
ation of cell membrane integrity, metabolic activity, apoptosis
induction, cellular morphology, and cell mobility.15b In addi-
tion, the existence of Si–O bonds in their architecture opens
the way to use them as drug delivery system by means of
the corresponding hydrolytic process. Dendrimers 2G-[Si(OCH2-
CH2NMe3+I−)]8 (1), 2G-[Si(OCH2CH2NMe3+I−)2]8 (2) and 2G-
[Si{O(CH2)2N(Me)(CH2)2NMe3+I−}]8 (3) were prepared accord-
ing to the reported methods.15 Dendrimer 2G-[Si{O(CH2)2-
N(Me)2+(CH2)2NMe3+(I−)2}]8 (4) containing 8 groups of doubled
methylated outer fragments was prepared by addition of 16 equiv-
alents of MeI to the corresponding amine-terminated dendrimer
2G-[Si{O(CH2)2N(Me)(CH2)2NMe2}]815 (see Experimental sec-
tion). Dendrimer 4 exhibits similar toxicity proﬁles to those shown
by dendrimer 3. The structures of the all dendrimers used in this
work are depicted in Fig. 1. First generation dendrimers were
too water-sensitive for chemical evaluation while those of the
third generation were not tested due to solubility problems. These
features precluded data rationalization on the basis of different
generations.
Dendriplexes were prepared as published elsewhere.15b Phos-
phorothioate ODNs used for binding studies were PPT and TAR,
15 or 16 bases in length respectively (see Experimental section)
and both ODNs showed identical behaviour. The interaction of
the dendriplexes, formed by dendrimers 1–4 and ODNs, with
BSA has been studied by agarose gel electrophoresis showing no
dissociation of the complexes in any case as is shown in Fig. 2.
For a more detailed study, dendriplex 3–ODN was chosen as an
example. The interactions of dendriplex 3–ODN with BSA and
with the anionic detergent sodium dodecyl sulfate (SDS) have
been studied by electrophoresis (see Fig. 3). The electrophoregram
showed different patterns of migration depending on the agent
used. ODN migration was retarded in the presence of BSA (see
entry 9) as indirect evidence of the formation of a complex between
ODN and proteins. The ODN migration pattern was also altered
in the presence of dendrimer 3 (entry 1) due to the formation
of a complex between the cationic dendrimer and the anionic
ODN as had been expected.13 Interestingly, when the dendriplexes
This journal is © The Royal Society of Chemistry 2007 Org. Biomol. Chem., 2007, 5, 1886–1893 | 1887
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Fig. 2 (A) Electrophoresis on a 3% agarose gel (stained with ethidium
bromide) of dendriplex formed by different carbosilane dendrimers and
TAR ODN in a ratio (+)–(−) 2 : 1 in the presence of increasing
concentrations of BSA. (B) The same gel stained with Blue Paragon
showing the protein migration. (1) ODN; (2) ODN + 10% BSA;
(3) 1–ODN + 10% BSA; (4) 3–ODN + 10% BSA; (5) 2–ODN + 10%
BSA; (6) 4–ODN + 10% BSA.
Fig. 3 (A) Electrophoresis on a 3% agarose gel (stained with ethidium
bromide) of dendrimer 3, ODN (TAR) or dendriplex 3–ODN in a ratio
(+)–(−) 2 : 1 in the absence or presence of increasing concentrations of
BSA or SDS. (B) The same gel stained with Blue Paragon showing the
protein migration. * denotes 100 bpDNA ladder as reference; (1) 3–ODN;
(2) 3–ODN + 2% BSA; (3) 3–ODN + 5% BSA; (4) 3–ODN + 10% BSA;
(5) 3–ODN + 0.5% SDS; (6) 3–ODN + 1% SDS; (7) 3–ODN + 2% SDS;
(8) 3–ODN + RPMI 1640 supplemented with serum (10% FCS);
(9) ODN + 10% BSA; (10) ODN.
3–ODN were challenged with increasing concentrations of BSA,
no changes in this migratory pattern were found (see entries 2–4)
proving that under these conditions, BSAwas not able to dissociate
the complex. However, the treatment with SDS in all the tested
concentrations disrupted the complex, allowing the ODN to be
electrophoresed and analyzed by its mobility in the gel (entries
5–7), also indicating that the nature of the complex union is based
on electrostatic interactions.
Further studies were conducted to evaluate ODN interactions
with proteins of AB human serum when the ODNs were naked
or alternatively complexed with dendrimers. Fig. 4 shows the
results of interactions between ODN and proteins of human
serum. Entries 2–4 clearly show the half migration of the ODN
in the presence of human AB serum with respect to the ODN
alone (entry 5). These results reveal the ODN union to human
serum proteins, which is conﬁrmed by the migration pattern of
the proteins (see Fig. 4B): proteins and ODN migrated at the
same level. Regarding the dendriplex 3–ODN, this was incubated
for 20 min prior to the addition of increasing amounts of serum
(see Fig. 5). When the dendriplex 3–ODN was challenged with
increasing concentrations of human AB serum, no changes in
this migratory pattern were found. ODN did not migrate towards
the positive pole (entries 3–5) and at the same time, the pattern of
Fig. 4 (A) Electrophoresis on a 3% agarose gel (stained with ethidium
bromide) of ODN (TAR) in the absence or presence of increasing
concentrations of AB human serum. (B) The same gel stained with Blue
Paragon showing the protein migration. * denotes 100 bp DNA ladder as
reference; (1) AB human serum; (2) ODN+ 20%AB; (3) ODN+ 10%AB;
(4) ODN + 5% AB; (5) ODN.
Fig. 5 (A) Electrophoresis on a 3% agarose gel (stained with ethidium
bromide) of dendrimer 3, ODN (PPT) or dendriplex 3–ODN in a ratio
(+)–(−) 2 : 1 in the absence or presence of increasing concentrations of
AB human serum. (B) The same gel stained with Blue Paragon showing
the protein migration. * denotes 100 bp DNA ladder as reference; (1) 20%
AB human serum; (2) 3–ODN; (3) 3–ODN + 5% AB; (4) 3–ODN + 10%
AB; (5) 3–ODN + 20% AB; (6) ODN + 5% AB; (7) ODN + 10% AB;
(8) ODN + 20% AB; (9) ODN; (10) 3 + 5% AB; (11) 3 + 10% AB; (12) 3 +
20% AB.
proteinmigrationwas just the same as that displayed by proteins of
the control (absence ofODNand dendrimer, entry 1) and the same
as the one exhibited by proteins in the presence of ODN (entries
6–8) or dendrimers (entries 10–12). These features indicate again
a protective effect of the dendrimer towards ODN from binding
to serum proteins. Only in the dendriplex challenged with 20%
of total serum (entry 5), a slight change in the ODN migration
was observed: most of the ODN did not migrate but a small part
did, to an intermediate position, similar to the pattern shown
for ODN in the presence of serum (entries 6–8). This could be
a consequence of the competition between dendrimer and serum
proteins for the ODN, resulting partially in ODN releasing from
theODN–dendrimer complex and further formation of theODN–
protein complex when a high concentration of proteins is present
in the medium. Finally, dendrimers without ODN did not change
the migratory pattern of the proteins, evidencing no interactions
between them, although a weak electrostatic interaction cannot
be ruled out (vide infra). Serum albumin has a net negative
charge but it is not uniformly charged within the structure and,
at physiological pH, domains I and II are negatively ionized while
domain III is weakly positively charged. Hence, the ODN can
interact with this domain III enabling the formation of a complex
between albumin andODN. In the case of ammonium-terminated
dendrimers, they may theoretically interact with both domains I
1888 | Org. Biomol. Chem., 2007, 5, 1886–1893 This journal is © The Royal Society of Chemistry 2007
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and II. The interacting ability of PAMAM with albumin has been
reported13b,16 and due to the low isoelectric point of albumin, it
interacts better with low protonated dendrimers than with the
highly protonated ones. The poor interaction of PAMAM with
albumin may indicate that the less polar sites of the dendrimers
are probably not accessible to the albumin hydrophobic residues,
and the weak polar interactions between the albumin hydrophilic
residues and the dendrimer surfacewould not allow any signiﬁcant
structural alteration of the dendrimer and albumin. Moreover,
it has been published that the binding of the dendrimers with
proteins mainly occurs when both electrostatic and hydrophobic
interactions take place.16 Perhaps a similar behaviour is occurring
in the case of the carbosilane dendrimer, showing a high charge
surface along with a high degree of hydrophobicity inside. Finally,
the electrostatic interaction between the ODN and the carbosilane
dendrimersmay prevent the interaction of the former with domain
III of the albumin.
In this study, both types of ODNs showed similar results as
mentioned. Although special attention was focused on detecting
possible differences, no changes were observed as described. The
presence of six guanines in the oligonucleotide against the PPT
element could cause different behaviour compared with that of
TAR, due to the possible formation of the G-tetrads. We believe
that the PPT oligonucleotide is probably not forming a very stable
quadruplex. All the guanines are at the 3′-end and are situated
in a row, so in order to form a quadruplex, four strands are
needed to bind each other to form an intermolecular quadruplex.
This type of quadruplex has been described to be less stable
than intramolecular quadruplexes.17 An oligonucleotide having
the six guanines separated in two groups of 3 guanines by 1–3
nucleotides will form a very stable quadruplex and hence, a more
stable bimolecular quadruplex may be formed.
Electrophoresis experiments were conﬁrmed by spectroﬂuori-
metric results. Since ODNs were labelled with ﬂuorescein, it was
possible to study changes in its rotational freedom in the presence
of BSA or dendrimers and in the system dendriplex + BSA. Again
the dendriplex 3–ODN has been elected as a representative
example. The rest of the dendriplexes formed by dendrimers 1,
2 and 4 afforded analogous results and a more detailed physico-
chemical study will be published separately.18 The increase of
the ﬂuorescence polarization of ﬂuorescein in the presence of
dendrimers (Fig. 6A) or in the presence of BSA (Fig. 6B) indicates
that ODNs were located in a more rigid environment. This is an
indirect proof thatODNs created complexes with both dendrimers
and BSA. However, it is worth mentioning that upon addition of
dendrimers, the enhancement of polarizationwas bigger than after
adding BSA. This may mean that the dendrimer–ODN union is
stronger than that of the protein–ODN. Moreover, the process of
forming complexes occurred at lower concentrations in the case of
dendrimers. Therefore, a lower number ofmolecules of dendrimers
were needed to complexODN, compared toBSA.WhenODNand
dendrimer 3 were preincubated for 15 minutes in a charge ratio
(+)–(−) 5 : 1 at different concentrations and then the complexes
were added to the BSA sample of constant concentration, no
changes in the polarization of ﬂuorescein (Fig. 6C) were observed.
The value of the polarization equalled the level of the plateau from
Fig. 6A. It means that the dendrimer–ODN complexes were stable
and, additionally, they were not disrupted by the protein presence.
Thus, this fact constitutes further evidence of the protective role of
Fig. 6 (A) Changes in the polarization of labelled ODN (TAR) upon
addition of dendrimer 3, CODN = 0.1 lM. (B) Changes in the polarization
of labelled ODN (TAR) upon addition of BSA, CODN = 0.1 lM.
(C) Changes in the polarization of labelled ODN (TAR) upon addition of
complex 3–ODN (ratio (+)–(−) 5 : 1) to BSA at a constant concentration
of 10 lM.
the carbosilane dendrimers for ODNs by preventing the formation
of complexes between ODNs and serum albumin.
It is possible that weak electrostatic interactions between BSA
and dendrimers can occur. In order to analyze them, BSA
labelled with Alexa Fluor 488 (AF488) was used. We observed
that dendrimer 3 quenched the ﬂuorescence of AF488 that was
attached to the surface of BSA (Fig. 7). Nevertheless, dendrimers
were not able to change the intensity of intrinsic ﬂuorescence of
BSA (Fig. 7). It means that the environment of the two trypto-
phans remained unchanged. Quenching of AF488 ﬂuorescence
might occur via direct contact between the dendrimer and the
ﬂuorophore. However, no changes in the intrinsic ﬂuorescence of
BSA means that dendrimers did not cause any conformational
disturbances within the protein molecule.
To conﬁrm the protection effect described above, a preliminary
biomedical study (toxicity, transfection andHIV inhibition assays)
This journal is © The Royal Society of Chemistry 2007 Org. Biomol. Chem., 2007, 5, 1886–1893 | 1889
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Fig. 7 Quenching of ﬂuorescence of tryptophans (CBSA = 5 lM) and
AF488 (CBSA = 20 lM) by dendrimer 3. F 0—the initial ﬂuorescence
intensity, F—the ﬂuorescence intensity after adding dendrimer 3.
of the use of dendriplexes in the presence of serum has been per-
formed in order to evaluate its consequences. In this study, we have
used dendrimers 3–4 and oligonucleotide sequences of different
length (TAR, GEM91 and REV) as potential inhibitors of the
HIV-1 virus (see Experimental section). The toxicity evaluation
of dendrimers 3–4 has been carried out by means of MTT and
LDH assays (see Fig. 8). ForMTT, peripheral bloodmononuclear
cells (PBMCs) treated with 3 and 4 at 1 lM in the presence of
10% of fetal calf serum (FCS) at 18 and 36 h presented similar
Fig. 8 (A) MTT assay at different times; (1) control; (2) DMSO 15%;
(3) dextran 5 lM; (4) dendrimer 3, 1 lM; (5) dendrimer 3, 5 lM; (6) dend-
rimer 4, 1 lM; (7) dendrimer 4, 5 lM. (B) LDH assay at different times;
(1) control; (2) triton x-100, 0.5%; (3) dextran 5 lM; (4) dendrimer 3, 1 lM;
(5) dendrimer 3, 5 lM; (6) dendrimer 4, 1 lM; (7) dendrimer 4, 5 lM.
mitochondrial activities (MA) to the control. However, toxicities
were increased around 20% when concentration was raised to
5 lM. In another toxicity approach, cell membrane damage was
measured by a lactate dehydrogenase (LDH) cytotoxicity assay.
Two different concentrations (1 and 5 lM) were tested over 1
and 18 h exposure. At the lower concentration, dendrimers 3–4
did not induce signiﬁcance LDH release (<5%). However, a 20%
increase of membrane damage was observed at 5 lM. To sum up,
both assays indicate the lack of toxicity of the dendrimers in the
presence of serum below 5 lM concentration.
Transfection of the dendriplex formed by 4 and ﬂuoresceinated
ODN (TAR) in PBMCs with a RPMI culture medium containing
10% of FCS was performed by confocal microscopy. Fig. 9
shows internalization and intracellular distribution of the ODN,
illustrating that the dendriplex is not deactivated before the
internalization process.
Fig. 9 (A) Confocal projection of six images of a representative T
lymphocyte incubated with 3–ODN-FITC (TAR) dendriplex (green) for
24 h. The plasma membrane and the nucleus are stained with CD45 (red)
and DAPI (blue), respectively. (B) Intensity proﬁle along the depicted line
inA (yellow). Note that most of 3–ODN is accumulated inside the nucleus.
Finally, HIV-1 inhibition assays using dendrimers 3–4 and the
corresponding dendriplexes formedwith single ODNs or cocktails
(see Experimental section) were determined via ELISA through
the evaluation of the p24 antigen release into culture supernatants
of MT-2 and PBMCs (see Fig. 10). Dendrimers by themselves
were not able to inhibit infection against HIV-1 (data not shown).
With respect to the MT-2 cell, higher inhibitions were found when
dendriplexes 4–ODN (TAR, 45%), 4–ODN (cocktail 1, 25%) and
4–ODN (cocktail 2, 53%) were used compared to ODNs alone
(see Fig. 10A). All these dendriplexes did not cause signiﬁcance
LDH release (<10%) (see Fig. 10B) indicating that the dendrimer
increases the inhibition efﬁciencywithout increasing toxicity in the
presence of 10% of FCS. Analogous results have been observed
in primary lines as PBMCs, more representative of physiological
systems and at the same time less resistant to in vitro treatment.
For instance, increased inhibition was found in the systems 3–
ODN (TAR, 18%) or 4–ODN (cocktail 1, 43%) with respect to
those observed for the ODN alone, both in the presence of serum
(Fig. 10C and D respectively). All these features are consistent
with a protective effect of the carbosilane dendrimers on the ODN
action in the presence of serum. It is worth noting from Fig. 10C
that inhibition was similar with the three sequences (antisense,
sense, random), showing a diminution of around 1/3 in the p24
levels with respect to the control of infected non-treated cells.
Thus, the inhibitory effects were due to non-sequence speciﬁc
effects, as described previously.19 However, the results observed in
1890 | Org. Biomol. Chem., 2007, 5, 1886–1893 This journal is © The Royal Society of Chemistry 2007
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Fig. 10 (A) ELISA assay for p24 antigen release in MT-2 cells after 24 h incubation with dendriplexes. (B) The corresponding LDH cytotoxicity assay
after 1 and 24 h. For A and B: (1) control; (2) dextran; (3) TAR; (4) 4–TAR; (5) cocktail 1; (6) 4–(cocktail 1); (7) cocktail 2; (8) 4–(cocktail 2). (C) and
(D) ELISA assay for p24 antigen release in PBMCs after 24 h incubation with dendriplexes. (C) (1) Control; (2) TAR; (3) TARs; (4) random; (5) 3–TAR;
(6) 3–TARs; (7) 3–random. (D) (1) Control; (2) dextran; (3) cocktail 1; (4) 4–(cocktail 1). Cocktails were an equimolecular mix of TAR + GEM91
(cocktail 1) or TAR + REV (cocktail 2) of ﬁnal concentration 0.5 lM.
the corresponding dendriplexes suggest some degree of speciﬁcity
when the dendrimer is present.
Conclusion
In conclusion, when ODNs form complexes with the carbosilane
dendrimers, the nucleic acid material is protected from binding to
proteins. Such protection could provide a meaningful advance for
therapies based on short nucleic acids. This could translate into a
reduction in the dose of ODN necessary to achieve the biological
effect. When a naked ODN is administered, it is necessary to
saturate all the possible binding sites within serum proteins to
have a fraction of free ODN able to reach the extravascular
space and perform the desired activity. If these interactions could
be prevented by the formation of a complex of ODNs with
a carbosilane dendrimer, presumably the saturation of binding
sites would no longer be necessary, resulting in the possibility
of administering smaller amounts of ODN. In addition, this
could reduce the toxic effects related to these unspeciﬁc unions
of the ODN to serum proteins. The toxicity measurements of
the dendrimers and the transfection of nucleic material using
the corresponding dendriplexes cultured in the presence of serum
show no alteration of such processes. The HIV inhibition assays,
also in the presence of serum, showan increase of 25–50%on going
from naked ODN to the corresponding dendriplex as evidence of
the protective effect mentioned above. Therefore, the carbosilane
dendrimers presented here are good candidates as carriers in
the context of biological applications of short nucleic acids and
perhaps even other anionic drugs.
Experimental
Dendrimers and ODNs synthesis
Dendrimers 1–3 were prepared according to reported methods.15
Oligonucleotideswere purchased fromEurogentec S.A. (Belgium).
The ODNs sequences correspond to antisense (complementary)
sequences of different HIV mRNAs: the HIV polypurine tract
(PPT) elementmRNA5′-ﬂuoresceine-TTTTCTTTTGGGGGG
3′, 15 bases; TAR 5′-GCT CCC GGG CTC GAC C-3′, 16 bases;
GEM 91 5′-CTC TCG CAC CCA TCT CTC TCC TTC T-3′, 25
bases; REV 5′-TCG TCG CTG TCT CCG CTT CTT CCT GCC
A-3′, 28 bases. TARs (sense) 5′-GGT CGA GCC CGG GAG C-
3′, 15 bases. Random 5′-GCC TCA CGC GCG CTC-3′, 15 bases.
Cocktails were a mix of TAR + GEM91 (cocktail 1) or TAR +
REV (cocktail 2).
Synthesis of 2G-[Si{O(CH2)2N(Me)2+(CH2)2NMe3+(I−)2}]8 (4).
Over a diethyl ether (10 mL) solution of 2G-[Si{O(CH2)2N-
(Me)(CH2)2NMe2}]815 (0.11 g, 0.04 mmol), a large excess of MeI
(0.06mL, 0.91mmol)was added.The resulting solutionwas stirred
for 48 h at room temperature and then evaporated under reduced
pressure to remove residual MeI. The residue was washed with
Et2O (2 × 5 mL) and dried under vacuum to give 4 as a white solid
This journal is © The Royal Society of Chemistry 2007 Org. Biomol. Chem., 2007, 5, 1886–1893 | 1891
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(0.18 g, 86%). 1H NMR (DMSO): d = 4.00 (16H, t, OCH2), 3.93
(32H,m, CH2N(Me2)+), 3.59 (16H, t, CH2N(Me)3+), 3.21 (120H, s
br, N(Me)2+ and N(Me)3+), 1.35 (24H, m, SiCH2CH2CH2SiO and
SiCH2CH2CH2Si), 0.72 (16H, m, SiCH2CH2CH2SiO), 0.56 (32H,
m, rest of the groups –CH2Si), 0.13 (48H, s, OSiMe2), −0.07
(12H, s, SiMe); 13C NMR (DMSO): d = 64.7 (OCH2), 56.3,
56.0, 55.7 (CH2N(Me2)+ and CH2N(Me)3+), 52.6 (NMe3+), 50.9
(NMe2+), 21.2–17.2 (groups –CH2– of the carbosilane skeleton),
−2.5 (OSiMe2), −5.5 (SiMe). Elemental analysis calcd (%) for
C128H316I16N16O8Si13: C, 33.40; H, 6.92; N, 4.87; found: C, 32.90;
H, 6.75; N, 4.57.
Electrophoresis measurements
(i) Formation of dendrimer–ODN complexes (dendriplexes): com-
plex formation between dendrimers and ODNs was carried out
using an electrostatic approach. Mixtures were achieved with an
excess of positive charge to provide enough positive charges to
be able to interact with the ODN. Consequently, dendrimers 1–4
were complexed with ODNs at an electrostatic charge ratio (+)–
(−) of 2 : 1. Ratios of ODN to dendrimer were based on the
calculation of the electrostatic charge present on each component,
e.g. the number of S− groups in the ODN vs. the number of
terminal ammonium groups on the dendrimer. As an example,
ODN and dendrimer 3 were diluted in sterile distilled water at
1 and 2 mg mL−1 respectively. 2.43 ll of ODN solution were
mixed with 3.25 ll of 3 solution in RPMI medium at a ﬁnal
volume of 60 ll, with an incubation time of 20 minutes at
room temperature. After this period of incubation, parts of the
mixtures of dendrimer–ODN were further exposed to increasing
concentrations of AB human serum in a ﬁnal volume of 100 ll of
RPMImedium (5%, 10%, 20%). (ii)Evaluation of dendrimer–ODN
complex formation and stability: after incubation of dendrimer and
ODN in the presence or absence of human AB serum, complex
formation and stability were assessed by evaluation of migration
retardation of ﬂuoresceinated ODNs during electrophoresis of
dendriplexes on 3%agarose gels.A 100bpDNA ladderwas used as
reference (Gibco BRLTM). Fluorescein enhances the ODN signal
markedly, facilitating the visualization of dendriplex migration
during electrophoresis. Additionally, the gel was polymerized
in the presence of ethidium bromide (EB) in order to make
more evident the ODN migration. (iii) Protein staining: after
electrophoresis was performed, a digital photo of the gel stained
with EB was taken; the same gel was later stained to evidence the
protein migration by treatment with Blue Paragon (Beckmann
CoulterTM) protein staining. Finally, the gel was washed by
immersion in a solution of 10% glacial acetic acid and a second
digital photo was taken.
Spectroﬂuorimetric measurements
Fluorescent measurements were carried out with a Perkin-Elmer
LS-50B spectroﬂuorometer. The excitation and emission wave-
lengths were 485 and 516 nm for ODNs labelled with ﬂuorescein;
295 and 350 nm for BSA intrinsic ﬂuorescence measurements; and
487 and 520 nm in the case of BSA labelled with Alexa Fluor 488
(AF488). The excitation and emission slit widths were set to 10
and 5 nm, respectively. Changes in the steady-state ﬂuorescence
polarization were monitored for ﬂuorescein that was a label in
ODN. Additionally, the intensity of intrinsic ﬂuorescence of BSA
and the intensity of the probe AF488 that was covalently attached
to BSA were measured.
Cells
PBMCs cells were derived from healthy voluntary donors, and
obtained from leukophoresed blood by FicollTM gradient and
elutriation centrifugation. Prior to investigation with dendrimers,
PBMCs were stimulated for 48 h with phytohemagglutinin
(2 lg mL−1) and interleukin 2 (IL-2, 100 IU mL−1). On the day
of the investigation, PBMCs were recovered and washed with
phosphate buffered saline (PBS), and then seeded in RPMI 1640
(Gibco) medium supplemented with 10% of fetal calf serum,
1% L-glutamine, antibiotics, and 50 IU mL−1 of IL-2, in a 5%
CO2 environment and 95% r. h. (relative humidity) (100 000 cells
per well in 96-well plates for the toxicity curve of dendrimer
concentrations). The ﬁnal volume in each well was 200 lL for
the 96-well plates and 500 lL for the 24-well plates. MT-2 is a cell
line transformed by human T-cell leukemia virus type 1 (HTLV-1)
and cells were seeded in the same conditions as PBMCs.
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide) assay
This method was selected to analyze detrimental intracellular
effects on mitochondria and metabolic activity. After 18 and
36 h of incubation of PBMCs with different concentrations of
dendrimers in a 96-well plate, culture medium containing the
dendrimers was replaced with 200 lL of serum-free Optimem.
20 lL of sterile ﬁltered MTT (Sigma) stock solution in PBS
pH 7.4 (5 mg mL−1) were added to each well to achieve a ﬁnal
concentration of 0.5 mg MTT mL−1. After 4 h, unreacted dye was
removed by aspiration and the formazan crystals were dissolved in
dimethyl sulfoxide (200 lL per well) (Sigma). The concentration
of formazan was then determined spectrophotometrically in a
plate reader (Biowhittaker microplate reader 2001, Innogenetics R©)
at a wavelength of 550 nm (test) and 690 nm (reference).
The spectrophotometer was calibrated to zero absorbance using
Optimem medium without cells. The relative cell viability (%)
related to control wells (cells with no dendrimer) was calculated
by [A] test/[A] control × 100. Each dendrimer concentration was
tested in triplicate, according to ATCC directives.
Lactate dehydrogenase (LDH) assay
The LDH concentration in these samples was assayed utilizing a
commercial kit (Cytotoxicity Detection Kit, Roche), allowing the
spectrophotometric determination of the nicotinamide adenine
dinucleotide (NAD) reduction at 490 nm in the presence of
lactate and LDH according to the manufacturer’s protocol. After
1 and 24 h of incubation of cells with different concentrations
of dendrimers in a 96-well plate, the supernatant was recovered.
Controls were performed with 0.1% (w/v) Triton X-100 and set
as 100% LDH release. The relative LDH release is deﬁned by the
ratio of LDH released over total LDH in the intact cells. Less than
10% LDH release was regarded as a non-toxic effect level in our
experiments. All samples were run in triplicate.
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Confocal microscopy
Cells for ﬂuorescence microscopy were treated with 0.8% Trypan
Blue (SigmaTM) for 5 min and then again washed twice with
PBS. TB positive cells exhibited membrane damage. In addition,
TB is an extra-cellular ﬂuorescence quenching agent. After TB
staining, cells were seeded on glass slides coatedwith poly-L-lysine,
ﬁxed with 3% paraformaldehyde, and labelled with a primary anti-
CD45 puriﬁed mouse anti-human monoclonal antibody (Becton
DickinsonTM). Samples were washed twice with PBS and then
incubated with a secondary antibody labelled in red (Texas
Red dye-conjugated AfﬁniPure F (ab)2 fragment goat anti-mouse
IgG + IgM (H + L), Jackson ImmunoResearchTM). Cells were
washed again twice with PBS. Finally, cells were treated for nuclear
staining with 4′,6′-diamidino-2-phenylindole (DAPI, VysysTM) for
10 min and washed three times with PBS. Samples were mounted
and images captured by a Leica TCS SP2 confocal microscope
using different lines of excitation: 405, 488 and 514 nm.
Enzyme immunoassay
The ODN concentration for complexes with carbosilane den-
drimers was 0.5 lM (1.27 lg). The concentrations of the den-
drimers were approximately 1 lM for ODN alone, and 2 lM
when complexed with cocktails (ﬁnal concentration in well). All
complexeswere formed in 50lLofPBS,with an incubation timeof
20min at room temperature.Cellswere infected at 0.05multiplicity
of infection (MOI)withHIV isolateNL4-3 for 2 h. Then, cells were
washed twice andmaintained in the same culturemediumas above,
supplemented with IL-2 (50 U mL−1) (300 000 cells per well in 24-
well plates). The ﬁnal volume for each well was 500 lL. ODN
alone and complexed with dendrimer were added to the wells.
The supernatant was collected at 24 h to evaluate antigen p24
by INNOTESTTM HIV antigen mAB (Innogenetics R©). Dextran
sulfate was purchased from Sigma (USA) and it was used as a
macromolecule control (polycation).
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